Immunex, The Johns Hopkins University deal

The parties will collaborate under a three-year agreement to develop a slow-release microsphere formulation of granulocyte-macrophage colony stimulating factor (GM-CSF) to treat cancer. IMNX (Seattle) received exclusive worldwide rights to the university's patent applications covering the use of controlled-release formulations of GM-CSF for immunotherapy. ...